Northstrive exits Bluejay Diagnostics stake in 13G

Northstrive Fund II LP and Braeden Lichti have fully exited their position in Bluejay Diagnostics, Inc. common stock.

Rhea-AI Filing Summary

Northstrive Fund II LP and Braeden Lichti have fully exited their position in Bluejay Diagnostics, Inc. common stock. In Amendment No. 1 to their Schedule 13G, they report that as of June 2, 2026, they beneficially own 0 shares, representing 0.00% of the company’s common stock. The amendment states that all previously held shares were sold and that they have ceased to be beneficial owners of more than five percent of the outstanding common stock. This amendment is identified as a final, or “exit,” filing for both reporting persons.

Key Figures

Beneficial ownership – Northstrive Fund II LP: 0 shares Beneficial ownership percentage – Northstrive Fund II LP: 0.00% Beneficial ownership – Braeden Lichti: 0 shares +1 more

4 metrics

Beneficial ownership – Northstrive Fund II LP 0 shares As of Amendment No. 1 to Schedule 13G

Beneficial ownership percentage – Northstrive Fund II LP 0.00% Percent of Bluejay Diagnostics common stock class

Beneficial ownership – Braeden Lichti 0 shares As of Amendment No. 1 to Schedule 13G

Date reporting persons ceased >5% ownership June 2, 2026 Item 5(e) exit date for more than five percent holder status

Key Terms

beneficially owns, Schedule 13G, exit filing, beneficial owners of more than five percent, +1 more

5 terms

beneficially owns financial

"As of the date of this Amendment, the Reporting Persons beneficially own 0 shares"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Schedule 13G regulatory

"This Amendment No. 1 relates to the Common Stock of the Issuer and amends the Schedule 13G."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

exit filing regulatory

"This Amendment is the final amendment to the and constitutes an exit filing for the Reporting Persons."

beneficial owners of more than five percent regulatory

"As of June 2, 2026, the Reporting Persons ceased to be beneficial owners of more than five percent"

sole voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: 7 | Sole Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Northstrive Fund II disclose about its Bluejay Diagnostics (BJDX) holdings?

Northstrive Fund II disclosed it no longer owns any Bluejay Diagnostics common stock. Amendment No. 1 to its Schedule 13G reports beneficial ownership of 0 shares, or 0.00% of the class, as of June 2, 2026, following complete disposition.

What did Braeden Lichti report in this Bluejay Diagnostics (BJDX) Schedule 13G amendment?

Braeden Lichti reported that he no longer beneficially owns any Bluejay Diagnostics common stock. The amendment states his beneficial ownership is 0 shares, or 0.00% of the class, after selling all previously owned shares by June 2, 2026.

Why is this Bluejay Diagnostics (BJDX) Schedule 13G amendment called an exit filing?

It is called an exit filing because both reporting persons now hold 0 shares. The amendment notes they ceased to be beneficial owners of more than five percent of Bluejay Diagnostics’ common stock as of June 2, 2026, making this their final amendment.

What percentage of Bluejay Diagnostics (BJDX) does Northstrive now own?

Northstrive now owns 0.00% of Bluejay Diagnostics’ outstanding common stock. The filing’s cover pages and Item 5 confirm that Northstrive Fund II LP has no sole or shared voting or dispositive power over any shares as of the amendment date.

When did Northstrive and Braeden Lichti cease being 5% holders of Bluejay Diagnostics (BJDX)?

They ceased being 5% holders on June 2, 2026. Item 5(e) states that as of June 2, 2026, the reporting persons were no longer beneficial owners of more than five percent of Bluejay Diagnostics’ outstanding common stock, triggering this exit amendment.

What type of security in Bluejay Diagnostics (BJDX) is covered by this amendment?

The amendment covers Bluejay Diagnostics’ common stock with $0.0001 par value per share. Item 1 lists this class of securities and confirms the filing relates specifically to the issuer’s common stock previously reported under the original Schedule 13G filed March 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 09:00 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Bluejay Diagnostics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

095633608

(CUSIP Number)

Ross. D. Carmel, Esq.
1185 Avenue of the Americas, 26th Floor,
New York, NY, 10036
(212) 930-9700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 095633608

1

Name of reporting person

NorthStrive Fund II LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.00 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP ("Northstrive Fund"). On June 2, 2026, Northstrive Fund sold all of its previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

SCHEDULE 13D

CUSIP Number(s): 095633608

1

Name of reporting person

Braeden Lichti

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.00 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

On June 2, 2026, Mr. Lichti sold all of his previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: Bluejay Diagnostics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 360 Massachusetts Avenue, Suite 203, Acton, MASSACHUSETTS , 01720.
Item 1 Comment: Mr. Braeden Lichti and Northstrive Fund previously filed a Schedule 13D on March 11, 2026. This Amendment No. 1 relates to the Common Stock of the Issuer and amends the Schedule 13G. The principal executive offices of the Issuer are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720. Explanatory Note: This Amendment No. 1 ("Amendment No. 1") amends the Schedule 13D ("Schedule 13D") filed with the U.S. Securities and Exchange Commission ("SEC") on March 11, 2026 relates to the common stock of Bluejay Diagnostics, Inc. ("Issuer"), owned by the reporting persons hereto ("Reporting Persons") and is the final amendment to the Schedule 13D and an exit filing for the Reporting Persons.
Item 2.	Identity and Background
(a)	Mr. Lichti serves as the Manager of Northstrive Fund. As of the date of this Amendment, neither Reporting Person beneficially owns any shares of the Issuer's Common Stock, as reflected on the cover pages and in Item 5.
(b)	The address of each of the Reporting Persons is 120 Newport Center Drive, Newport Beach, CA 92660.
(c)	Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company.
(d)	Mr. Lichti has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).
(e)	None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
(f)	Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable. This Amendment reports only the disposition of all shares previously reported on the Schedule 13D and no additional securities were acquired since the Schedule 13D filed with the SEC on March 11, 2026 As of the date of this Amendment, the Reporting Persons beneficially own 0 shares of the Issuer's Common Stock.
Item 4.	Purpose of Transaction
	Since the filing of the Reporting Persons' Schedule 13D with the SEC on March 11, 2026, the Reporting Persons have disposed of all shares of common stock of the Issuer. As of June 2, 2026, the Reporting Persons no longer beneficially own any shares of the Issuer's Common Stock.
Item 5.	Interest in Securities of the Issuer
(a)	As of the date of this Amendment, the Reporting Person do not beneficially own any shares of the Issuer's common stock. The information set forth on the cover pages of this Amendment is incorporated herein by reference.
(b)	Sole power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Shared power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Sole power to dispose or to direct the disposition of: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Shared power to dispose or to direct the disposition: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares
(c)	The information set forth in Item 3 above is incorporated herein by reference.
(d)	Not applicable.
(e)	As of June 2, 2026, the Reporting Persons ceased to be beneficial owners of more than five percent of the Issuer's outstanding Common Stock. This Amendment is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information in Items 3 and 4 is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

NorthStrive Fund II LP

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti/Manager
Date:	06/02/2026

Braeden Lichti

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti/Manager
Date:	06/02/2026